Feb 9, 2012 | Business Journal
Glaucoma drug developer Altheos adds $12.5M to Series A round
Altheos Inc. raised an additional $12.5 million - pushing its Series A round to a total of $32.5 million - as the South San Francisco company enters a mid-stage study of a glaucoma drug.
Press Release News From 24-7 Press Re...
Barbara Wirostko, Altheos - presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA
Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio's 3rd Ocular Disease & Drug Discovery Conference, May 26-27, 2011 in Boston, MA.
Barbara Wirostko, Altheos Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA
Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio's 3rd Ocular Disease & Drug Discovery Conference, May 26-27, 2011 in Boston, MA.
Chief medical officer named at Altheos
Dr. Barbara Wirostko was named chief medical officer of biopharm Altheos Inc. on Thursday.